About: Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?
Creator	Ippolito, Giuseppe Vairo, Francesco Zumla, Alimuddin Apolone, Giovanni Baritussio, Aldo Cavuto, Silvio Girardi, Enrico Gostin, Lawrence Kremsner, Peter Krishna, Sanjeev Lanini, Simone Pletschette, Michel Portella, Gina Satolli, Roberto Strada, Gino Caro, Antonino Ioannidis, John
Source	Elsevier; Medline; PMC
abstract	The Ebola outbreak that has devastated parts of west Africa represents an unprecedented challenge for research and ethics. Estimates from the past three decades emphasise that the present effort to contain the epidemic in the three most affected countries (Guinea, Liberia, and Sierra Leone) has been insufficient, with more than 24 900 cases and about 10 300 deaths, as of March 25, 2015. Faced with such an exceptional event and the urgent response it demands, the use of randomised controlled trials (RCT) for Ebola-related research might be both unethical and infeasible and that potential interventions should be assessed in non-randomised studies on the basis of compassionate use. However, non-randomised studies might not yield valid conclusions, leading to large residual uncertainty about how to interpret the results, and can also waste scarce intervention-related resources, making them profoundly unethical. Scientifically sound and rigorous study designs, such as adaptive RCTs, could provide the best way to reduce the time needed to develop new interventions and to obtain valid results on their efficacy and safety while preserving the application of ethical precepts. We present an overview of clinical studies registered at present at the four main international trial registries and provide a simulation on how adaptive RCTs can behave in this context, when mortality varies simultaneously in either the control or the experimental group.
has issue date	2015-04-14(xsd:dateTime)
bibo:doi	10.1016/s1473-3099(15)70106-4
bibo:pmid	25881871
has license	no-cc
sha1sum (hex)	7738dbffafaefd40ae2b91ef52c3c127655f92e7
schema:url	https://doi.org/10.1016/s1473-3099%2815%2970106-4
resource representing a document's title	Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?
has PubMed Central identifier	PMC7129402
has PubMed identifier	25881871
schema:publication	Lancet Infect Dis
resource representing a document's body	covid:7738dbffafaefd40ae2b91ef52c3c127655f92e7#body_text
is schema:about of	named entity 'EBOLA' named entity 'adaptive' named entity 'waste' named entity 'ethics' named entity 'sound' named entity 'Estimates' named entity 'studies' named entity 'OUTBREAK' named entity 'NON-RANDOMISED STUDIES' named entity 'TRIAL' named entity 'CONTROL' named entity 'SIMULATION' named entity 'SIMULTANEOUSLY' named entity 'LARGE' named entity 'OVERVIEW' named entity 'REGISTRIES' named entity 'INTERVENTIONS' named entity '2015' named entity 'EVENT' named entity 'STUDY' named entity 'REGISTERED' named entity 'DEATHS' named entity 'BEST' named entity 'RESEARCH' named entity 'RANDOMISED CONTROLLED TRIALS' named entity 'SOUND' named entity 'APPLICATION' named entity 'ETHICS' named entity 'LEADING' named entity 'ORT' named entity 'PAST' named entity 'SAFETY' named entity 'ASSESSED' named entity 'OBTAIN' named entity 'COMPASSIONATE USE' covid:arg/7738dbffafaefd40ae2b91ef52c3c127655f92e7 named entity 'RANDOMISED TRIALS' named entity 'PERSONAL' named entity 'ADDRESS' named entity 'VIEW' named entity 'ESTIMATES' named entity '900' named entity 'VALID' named entity 'NEW' named entity 'WAY' named entity 'BEST' named entity 'OUTBREAK' named entity 'NON-RANDOMISED STUDIES' named entity 'VARIES' named entity 'CASES' named entity 'RELATED' named entity 'FOR RESEARCH' named entity 'NEEDED' named entity 'THEIR' named entity 'WASTE' named entity 'POTENTIAL' named entity 'PRESENT' named entity 'MORTALITY' named entity 'DEMANDS' named entity 'LIBERIA' named entity 'RESULTS' named entity 'EXPERIMENTAL GROUP' named entity 'RESPONSE' named entity 'TIME' named entity 'PRESERVING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software